LEO 35299

LEO 35299 is a small molecule drug developed by LEO Pharma as a topical agent for the treatment of inflammatory skin conditions, particularly psoriasis and psoriasis vulgaris. It has been described both as a potent topical corticosteroid and as a C-X-C motif chemokine receptor 4 (CXCR4) antagonist with immunomodulatory properties. The drug was evaluated in clinical trials to assess its anti-psoriatic effects using plaque test models, but its highest development status remains at Phase 1 or pending, with no evidence of approval or further advancement. Its mechanism of action involves antagonism of the C-X-C motif chemokine receptor 4 (CXCR4), which plays a role in immune cell trafficking and inflammation modulation[1][2][3].